SEC Tracker
Get the app

GoodRx Holdings GDRX

GoodRx Holdings Q1 FY24: revenue $197.9M; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers GoodRx Holdings reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$197.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$1.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$0.00No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$533.3MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations$42.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when GoodRx Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 7374 and related industry codes: the same peer list as the financial tables.

  1. Appian APPN
  2. Bandwidth BAND public float $431M, Jun 30, 2025
  3. IBEX IBEX public float $431M, Dec 31, 2025
  4. Nextdoor Holdings NXDR public float $434M, Jun 30, 2025
  5. Veradigm MDRX public float $408M, Jun 30, 2025